3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Gynecologic
2
Genitourinary
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
8
Brain Neoplasms
8
Neoplasm Metastasis
4
Meningeal Carcinomatosis
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Astrocytoma
1
Interventions
Gemcitabine
5
Temozolomide
3
Paclitaxel
3
Oxaliplatin
3
Nivolumab
3
Leucovorin
3
Irinotecan
3
Erlotinib Hydrochloride
3
Bevacizumab
3
ulixertinib
2
tovorafenib
2
pembrolizumab
2
Trastuzumab
2
Specimen Handling
2
Radiotherapy
2
Magnetic Resonance Spectroscopy
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Docetaxel
2
Cyclophosphamide
2
Cetuximab
2
Carboplatin
2
vocimagene amiretrorepvec
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
temsirolimus
1
spartalizumab
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
trastuzumab deruxtecan
×
CNS
×
Clear all
NCT05417594
2026-05-05
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled